Phase II, Randomized Double-blind Study of Efficacy and Safety of Two Dose Levels of LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Trial Profile

Phase II, Randomized Double-blind Study of Efficacy and Safety of Two Dose Levels of LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Sonidegib (Primary)
  • Indications Basal cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BOLT
  • Sponsors Novartis
  • Most Recent Events

    • 12 Sep 2017 30-month results presented at the 42nd European Society for Medical Oncology Congress.
    • 10 Jan 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 23 Sep 2016 Results of pooled analysis of this and other three studies on patients and four on volunteers published in the European Journal of Clinical Pharmacology (2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top